Blog y noticias


On Wednesday 3rd April, Dr+Vet was honoured to welcome leading veterinary ophthalmologist Maria Simó for our first webinar on Keratoconjunctivitis Seca (KCS) in dogs. During this virtual event, María Simó shared her knowledge and experience in the diagnosis and treatment of this common but often underestimated eye disease. Today, we can finally announce that the full video, with subtitles in English (and other languages automatically), is available for viewing on our blog and our YouTube channel! Attached to this article, you will find the direct link to the video so you can access it and deepen the knowledge shared by María Simó.

About Maria Simó:

Maria Simó is a renowned veterinary ophthalmologist with a solid background and extensive experience in the field of veterinary ophthalmology. Graduated in Veterinary Medicine from the Autonomous University of Barcelona, María has completed several postgraduate courses and works as an ophthalmologist at the prestigious Instituto Veterinario Oftalmológico (IVO) in Barcelona.

Contenido del Webinar:

Maria Simó talked us through the basics of Keratoconjunctivitis Seca, from diagnostic methods to the most effective treatment options, exploring in detail how to approach this disease in a comprehensive way.

One of the main conclusions of the webinar was the importance of not relying solely on the Schirmer test to diagnose KCS. María Simó emphasised the need for a complete and detailed assessment, as well as the use of additional diagnostic tools for a correct diagnosis, as without all the information, ineffective treatments may be prescribed. She also talked about the importance of referring cases that do not resolve correctly in order to fully evaluate them.


We thank all participants for their support.

The webinar on Keratoconjunctivitis Seca with Maria Simó was a great success, and we would like to thank everyone who joined us for this educational event. We hope that this resource will be a valuable source of information for all veterinarians interested in veterinary ophthalmology. Feel free to check out the full video and share it with your colleagues.

Stay tuned to our social media and website for more information on future of Dr+Vet events and educational resources!


One of our two new Fall releases from Dr+Vet: the new and improved Occulus+.

This new version incorporates alpha lipoic acid and has been designed to achieve greater efficacy in lens nutrition and better protection of the visual health of dogs and cats at risk of developing geriatric, diabetic or hypocalcemia cataracts.

What is alpha lipoic acid?
Alpha lipoic acid, present in Occulus+, is an antioxidant that occurs naturally in the body and is also found in food. It is used to break down carbohydrates and generate energy. Alpha lipoic acid acts as an aldose reductase inhibitor and in combination with its ability to regenerate glutathione, coenzyme Q10 and vitamins C and E to their reduced forms, make it a potent weapon against lipid oxidation.

Its benefits for vision
Studies have shown that topical use of an aldose reductase inhibitor can prevent cataracts in diabetic dogs. Also, oral administration of alpha lipoic acid along with other antioxidants has been shown to delay the onset of cataracts in dogs, and has even shown improvement in cases where cataracts had already developed.

The usual components
We would like to remind you of the ingredients that were already part of the formula, and that continue to be essential to provide eye care:
Lutein and Zeaxanthin: These carotenoids from the Marigold flower, naturally present in the lens, have the ability to filter and absorb potentially harmful short wavelength light, reducing oxidative stress.
Minerals (Zinc and Copper): Zinc, with its antioxidant effect, and its relationship with copper, play an important role in maintaining normal ocular function and reducing oxidative stress.
Mineral (Calcium): As an essential component of aqueous humor, calcium influences ocular health and contributes to the prevention of cataracts due to hypocalcemia.
Vitamins A, C, E, D3 and K: These vitamins can protect the lens against the development and progression of cataracts, thanks to their antioxidant properties. Vitamins K and D3 have antioxidant and anti-inflammatory properties.
B vitamins: Vitamins B2, B3, B6 and B12 play a role in the prevention of nuclear and cortical opacities in the lens through their ability to maintain the cellular response to oxidative stress.

New 4-part divisible tablet format
With the new 4-part divisible format, we offer the possibility to adjust the dosage of Occulus+ according to the individual needs of each pet. This new format makes dosing more personalized and precise than with the old format.

Why Occulus+:
With Occulus+, we are redefining eye care for your pets. Administering eye drops directly into the eyes can be a challenge for both owners and pets. Discomfort and resistance to application can create a stressful experience for both. In contrast, with oral administration of vitamins in tablet form, the stress and anxiety associated with the process is significantly reduced. Oral administration is generally more acceptable to pets than the application of eye drops. Tablets, in the case of Occulus+, are generally easier to administer due to their format and palatability ensuring consistency and compliance with treatment.

How to get Occulus+?
To purchase Occulus+, you can obtain it exclusively through veterinary distributors in specialized clinics. This guarantees that you receive the product under the guidance and supervision of animal health professionals.

At Dr+Vet, our commitment is clear: to offer cutting-edge solutions for the well-being of your furry companions.


From Dr+Vet we are pleased to announce our improvement in the formula of our classic Glauco, the veterinary nutraceutical focused to provide nutrients to the retina and offer neuroprotection to the optic nerve to prevent its degeneration, very relevant in cases of Glaucoma.

Glaucoma is a progressive optic retinopathy and one of the major causes of blindness in humans, it is characterized by optic nerve degeneration, loss of retinal ganglion cells (RGC) and cause restructuring of nerve tissues, causing visual loss.
The factors causing this condition are diverse and complex. Increased intraocular pressure (IOP) has been identified as one of the main drivers of glaucoma and is also the mainstay in the treatment of this disease, focusing on topical and systemic IOP-lowering treatments. Although even though IOP can be effectively controlled, there are patients whose disease still progresses, causing irreversible vision loss.
It is for this reason that Dr+Vet created Glauco+, a nutritional supplement with several natural components that help to generate positive effects on the retina and offer protection against the progression of this disease. Through the incorporation of Citicoline, a molecule that has demonstrated its potential in studies on neurodegenerative diseases, we are opening a door towards a more complete approach to the management of glaucoma in our pets.

Discovering the Potential of Citicoline
In the constant quest to improve treatments for glaucoma in pets, ophthalmic specialists have played a key role in the evolution of therapeutic options. It is for this reason that the incorporation of citicoline in the Glauco+ formula has been a long-awaited and much-requested addition by these eye health experts. Citicoline has garnered considerable attention in the field of neurodegenerative diseases. Research in human medicine has shown its potential benefits in conditions such as senile dementia, Parkinson’s disease and glaucoma. Its introduction in Glauco+ aims to take advantage of these potential benefits for pets.

Citicoline, also known as cytidine-5′-diphosphocholine, is essential for synthesizing membrane phospholipids, including phosphatidylcholine. This compound participates in several metabolic pathways, playing roles in phospholipid homeostasis, mitochondrial dynamics and neurotransmission, especially in the complex mechanism of visual transmission.
When administered orally, Citicoline is efficiently absorbed in the intestines, being transformed into choline and cytidine in the digestive tract and liver. These compounds cross the blood-brain barrier, becoming precursors of vital metabolites. These include phospholipids, nucleic acids, proteins, sphingomyelin, cardiolipin and acetylcholine, a major neurotransmitter in the cholinergic system that modulates visual processes.
In human clinical studies, the ability of citicoline to counteract glutamate-mediated excitotoxicity and oxidative stress, factors that play a crucial role in glaucoma-associated neuronal damage, has been observed. In addition, its influence on the regulation of neurotransmitters such as dopamine and acetylcholine has been linked to improvements in visual function, which translates into a positive impact on quality of life.

Not only has citicoline been shown to protect damaged retinal ganglion cells, but it also acts to improve mitochondrial function and cell membrane integrity. These effects are particularly relevant in the context of glaucoma, where mitochondrial aging processes and neuronal axon damage are characteristic features of the disease.

The classic Glauco components are still present
The Glauco+ approach is based on the combination of natural components, each with its own unique properties and benefits. These components have been selected to address multiple factors, providing a comprehensive solution.
Ginkgo biloba: Native to Asia, this medicinal plant has been appreciated for its properties in traditional medicine for centuries. The extracts of its leaves are rich in flavonoids and terpenoids, which have shown beneficial effects on blood circulation, reduction of blood viscosity, increase in retinal blood flow and neuroprotection.
Anthocyanins (Vaccinium myrtillus, wild blueberry): These natural pigments, present in fruits and vegetables, help improve blood circulation and show antioxidant action. They have an affinity for vascular tissues and have been recognized as beneficial for eye health. Anthocyanins have been shown to contribute to the normalization of retinal blood flow.
Vitamin B3 (Niacinamide or Nicotinamide): This essential vitamin acts as a precursor to the coenzyme nicotinamide adenine dinucleotide (NAD+), vital for mitochondrial function and energy production in retinal ganglion cells. The decrease in NAD+ levels with age and in neurodegenerative diseases, such as glaucoma, has been documented. Supplementation with vitamin B3 has been shown to be a powerful neuroprotectant, preventing neuronal damage and mitochondrial dysfunction.
Vitamin B9 (folic acid) and Vitamin B12 – These B vitamins play a key role in regulating levels of homocysteine, an amino acid linked to retinal damage. The relationship between elevated homocysteine levels and eye damage has been highlighted in several studies. Taking vitamins B12 and B9, in particular, has been associated with reducing homocysteine levels, which could be beneficial in preventing this form of damage.

New tablet format divisible into 4 parts
With the new format divisible into 4 parts, we offer the possibility of adjusting the dose of Glauco+ according to the individual needs of each pet. This new format makes dosing more personalized and precise than with the old format. Offering the possibility of dosing from 2.5kg onwards.
How to get Glauco+?
To purchase Glauco+, you can obtain it exclusively through veterinary distributors in specialized clinics. This measure guarantees that you receive the product under the guidance and supervision of animal health professionals.

In summary
The inclusion of citicoline in Glauco+ represents a step forward in the search for more complete dietary supplements for the eye health of pets. The support and recommendation of ophthalmologists specialized in ocular health are the basis for the development of new and improved products focused especially on veterinary medicine.

From Dr+Vet we want to remember that Glauco+ will be available from November and that at AVEPA-SEVC we will be presenting the product.

Copyright by Boothmen Pharma 2023. All rights reserved.